It is our great pleasure to invite you to the 6th International Chicago Lymphoma Symposium, dedicated in part to commemorating the lifelong contributions of Dr. John E. Ultmann to the study of lymphoproliferative disorders. Dr. John E. Ultmann, a pioneer in the treatment of lymphoma, devoted his life to the understanding of this disease. He was particularly known for his work on the precise staging of Hodgkin lymphoma and the utility of staging as a guide for treatment.

The John E. Ultmann Keynote Address, in conjunction with the 6th International Chicago Lymphoma Symposium, has been established to honor his achievements and to look ahead at how insights in biology and classification influence novel treatment strategies. This year’s keynote will be given by Professor Michael Pfreundschuh, Professor for Internal Medicine at Saarland University Medical School and a founding member and Chairman of the German High Grade Non-Hodgkin-Lymphoma Study Group (DSHNHL).    Professor Pfreundschuh will address the current and future perspectives surrounding the clinical approach and treatment of diffuse large B-cell lymphoma (DLBCL).

Chicago is a city rich in academic tradition, and we welcome you to join us at the only dedicated lymphoma symposium in the Midwest. Given the current pace of increasing information and knowledge, there is an important need to discuss the growing body of data regarding the biology and treatment of patients with Hodgkin disease and non-Hodgkin lymphoma in a peer to peer format. Our stellar speakers’ list draws from local, national, and international expertise.

The format of the meeting includes a combination of expert presentations, interactive case discussions, poster/abstract presentations, and an opportunity for question-and-answer debates. Based on favorable feedback, we are expanding the ICLS meeting to a 2-day meeting to be held Friday afternoon and Saturday morning/early afternoon. Friday afternoon will concentrate on the scientific and translational aspects of lymphoma, while Saturday will have a clinical focus. 

The Friday portion of the meeting will include abstract/poster presentations on cutting-edge lymphoma research and will include a wine and cheese reception. Part of Saturday’s meeting will include an academic debate discussion (pros/cons) regarding the merits of autologous transplantation in follicular lymphoma. In addition, ICLS meeting participants will be able to submit lymphoma “challenging cases” prior to the meeting that will be openly discussed among a panel of lymphoma experts.

The symposium has been designed for medical hematologists/oncologists, radiation oncologists, pathologists, surgical oncologists, fellows in training, oncology nurses and allied health professionals.

After this symposium, participants will be able to:

• Recognize the relevance of the tumor microenvironment as it pertains to non-Hodgkin’s lymphoma.
• Discuss the biologic predictors and implications on treatment in follicular lymphoma.
• Discuss the role of stem cell transplantation in follicular lymphoma.
• Review the emerging pathways and associated targeted treatment options for patients with Hodgkin disease.
• Demonstrate knowledge on the treatment strategies available for patients with mantle cell lymphoma.
• Evaluate the available treatment options for patients with newly diagnosed chronic lymphocytic leukemia.

We look forward to welcoming you in Chicago!

^ TOP